Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Illumina Inc. (NASDAQ:ILMN)

Analysis of Profitability Ratios

Beginner level

Profitability Ratios (Summary)

Illumina Inc., profitability ratios

Microsoft Excel LibreOffice Calc
Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Jan 1, 2017 Jan 3, 2016
Return on Sales
Gross profit margin 69.63% 69.01% 66.35% 69.48% 69.80%
Operating profit margin 27.80% 26.49% 22.02% 24.48% 27.61%
Net profit margin 28.28% 24.78% 26.38% 19.29% 20.79%
Return on Investment
Return on equity (ROE) 21.72% 21.98% 26.41% 21.06% 24.97%
Return on assets (ROA) 13.70% 11.87% 13.81% 10.81% 12.52%

Based on: 10-K (filing date: 2020-02-11), 10-K (filing date: 2019-02-12), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-14), 10-K (filing date: 2016-03-02).

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Illumina Inc.’s gross profit margin ratio improved from 2017 to 2018 and from 2018 to 2019.
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Illumina Inc.’s operating profit margin ratio improved from 2017 to 2018 and from 2018 to 2019.
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Illumina Inc.’s net profit margin ratio deteriorated from 2017 to 2018 but then improved from 2018 to 2019 exceeding 2017 level.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Illumina Inc.’s ROE deteriorated from 2017 to 2018 and from 2018 to 2019.
ROA A profitability ratio calculated as net income divided by total assets. Illumina Inc.’s ROA deteriorated from 2017 to 2018 but then improved from 2018 to 2019 not reaching 2017 level.

Gross Profit Margin

Illumina Inc., gross profit margin calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Jan 1, 2017 Jan 3, 2016
Selected Financial Data (US$ in millions)
Gross profit 2,467  2,300  1,826  1,666  1,549 
Revenue 3,543  3,333  2,752  2,398  2,220 
Profitability Ratio
Gross profit margin1 69.63% 69.01% 66.35% 69.48% 69.80%
Benchmarks
Gross Profit Margin, Competitors2
Abbott Laboratories 52.46% 51.32% 47.75% 54.09% 54.19%
AbbVie Inc. 77.64% 76.44% 75.05% 77.25% 80.31%
Amgen Inc. 80.38% 81.80% 81.33% 80.99% 79.82%
Biogen Inc. 86.40% 86.50% 86.72% 87.08% 88.48%
Bristol-Myers Squibb Co. 69.10% 70.98% 70.80% 74.54% 76.39%
Eli Lilly & Co. 78.85% 73.81% 73.46% 73.35% 74.76%
Gilead Sciences Inc. 78.86% 77.61% 82.97% 85.77% 87.54%
Johnson & Johnson 66.42% 66.79% 66.84% 69.84% 69.27%
Merck & Co. Inc. 69.87% 68.06% 68.16% 65.10% 62.19%
Pfizer Inc. 80.25% 79.03% 78.61% 76.66% 80.25%
Regeneron Pharmaceuticals Inc. 90.05% 93.53% 93.24% 93.83% 90.43%
Vertex Pharmaceuticals Inc. 86.84% 86.56% 88.95% 87.64% 87.94%
Zoetis Inc. 68.18% 67.19% 66.55% 65.92% 63.53%

Based on: 10-K (filing date: 2020-02-11), 10-K (filing date: 2019-02-12), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-14), 10-K (filing date: 2016-03-02).

1 2019 Calculation
Gross profit margin = 100 × Gross profit ÷ Revenue
= 100 × 2,467 ÷ 3,543 = 69.63%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Illumina Inc.’s gross profit margin ratio improved from 2017 to 2018 and from 2018 to 2019.

Operating Profit Margin

Illumina Inc., operating profit margin calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Jan 1, 2017 Jan 3, 2016
Selected Financial Data (US$ in millions)
Income from operations 985  883  606  587  613 
Revenue 3,543  3,333  2,752  2,398  2,220 
Profitability Ratio
Operating profit margin1 27.80% 26.49% 22.02% 24.48% 27.61%
Benchmarks
Operating Profit Margin, Competitors2
Abbott Laboratories 14.21% 11.94% 6.30% 15.27% 14.05%
AbbVie Inc. 39.03% 19.49% 33.99% 36.60% 32.97%
Amgen Inc. 43.57% 45.55% 45.76% 44.74% 40.44%
Biogen Inc. 48.98% 43.77% 43.54% 44.99% 45.44%
Bristol-Myers Squibb Co. 22.62% 22.69% 17.39% 23.83% 11.41%
Eli Lilly & Co. 22.29% 15.15% 9.38% 16.30% 13.47%
Gilead Sciences Inc. 19.38% 37.83% 55.04% 58.87% 69.03%
Johnson & Johnson 24.15% 24.27% 24.07% 28.72% 25.05%
Merck & Co. Inc. 24.77% 19.62% 16.28% 13.51% 17.54%
Pfizer Inc. 25.46% 26.10% 25.92% 22.73% 24.20%
Regeneron Pharmaceuticals Inc. 28.10% 37.77% 35.41% 27.38% 30.51%
Vertex Pharmaceuticals Inc. 28.77% 20.84% 4.95% 0.58% -45.23%
Zoetis Inc. 31.42% 31.12% 32.15% 28.48% 15.74%
Operating Profit Margin, Sector
Pharmaceuticals & Biotechnology 26.77% 25.01% 26.00% 28.77% 28.33%
Operating Profit Margin, Industry
Health Care 19.26% 18.28% 18.86% 20.13% 20.25%

Based on: 10-K (filing date: 2020-02-11), 10-K (filing date: 2019-02-12), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-14), 10-K (filing date: 2016-03-02).

1 2019 Calculation
Operating profit margin = 100 × Income from operations ÷ Revenue
= 100 × 985 ÷ 3,543 = 27.80%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Illumina Inc.’s operating profit margin ratio improved from 2017 to 2018 and from 2018 to 2019.

Net Profit Margin

Illumina Inc., net profit margin calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Jan 1, 2017 Jan 3, 2016
Selected Financial Data (US$ in millions)
Net income attributable to Illumina stockholders 1,002  826  726  463  462 
Revenue 3,543  3,333  2,752  2,398  2,220 
Profitability Ratio
Net profit margin1 28.28% 24.78% 26.38% 19.29% 20.79%
Benchmarks
Net Profit Margin, Competitors2
Abbott Laboratories 11.56% 7.74% 1.74% 6.71% 21.68%
AbbVie Inc. 23.69% 17.36% 18.82% 23.22% 22.50%
Amgen Inc. 35.32% 37.25% 9.08% 35.27% 33.13%
Biogen Inc. 40.96% 32.93% 20.69% 32.34% 32.95%
Bristol-Myers Squibb Co. 13.15% 21.81% 4.85% 22.94% 9.45%
Eli Lilly & Co. 37.27% 13.16% -0.89% 12.90% 12.07%
Gilead Sciences Inc. 24.35% 25.16% 18.03% 45.07% 56.32%
Johnson & Johnson 18.42% 18.75% 1.70% 23.01% 21.99%
Merck & Co. Inc. 21.01% 14.71% 5.97% 9.85% 11.25%
Pfizer Inc. 31.45% 20.79% 40.55% 13.66% 14.25%
Regeneron Pharmaceuticals Inc. 26.91% 36.42% 20.41% 18.42% 15.50%
Vertex Pharmaceuticals Inc. 28.27% 68.80% 10.59% -6.58% -53.89%
Zoetis Inc. 23.96% 24.52% 16.28% 16.80% 7.11%
Net Profit Margin, Sector
Pharmaceuticals & Biotechnology 23.87% 20.29% 12.71% 21.05% 22.22%
Net Profit Margin, Industry
Health Care 16.89% 14.36% 10.18% 14.42% 15.44%

Based on: 10-K (filing date: 2020-02-11), 10-K (filing date: 2019-02-12), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-14), 10-K (filing date: 2016-03-02).

1 2019 Calculation
Net profit margin = 100 × Net income attributable to Illumina stockholders ÷ Revenue
= 100 × 1,002 ÷ 3,543 = 28.28%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Illumina Inc.’s net profit margin ratio deteriorated from 2017 to 2018 but then improved from 2018 to 2019 exceeding 2017 level.

Return on Equity (ROE)

Illumina Inc., ROE calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Jan 1, 2017 Jan 3, 2016
Selected Financial Data (US$ in millions)
Net income attributable to Illumina stockholders 1,002  826  726  463  462 
Total Illumina stockholders’ equity 4,613  3,758  2,749  2,197  1,849 
Profitability Ratio
ROE1 21.72% 21.98% 26.41% 21.06% 24.97%
Benchmarks
ROE, Competitors2
Abbott Laboratories 11.86% 7.76% 1.54% 6.82% 20.85%
AbbVie Inc. 104.16% 128.41% 130.39%
Amgen Inc. 81.07% 67.15% 7.84% 25.85% 24.71%
Biogen Inc. 44.13% 33.98% 20.13% 30.50% 37.84%
Bristol-Myers Squibb Co. 6.66% 35.07% 8.58% 27.55% 10.97%
Eli Lilly & Co. 319.09% 32.88% -1.76% 19.54% 16.53%
Gilead Sciences Inc. 23.91% 25.51% 22.64% 71.48% 97.70%
Johnson & Johnson 25.42% 25.60% 2.16% 23.49% 21.66%
Merck & Co. Inc. 37.99% 23.30% 6.97% 9.78% 9.94%
Pfizer Inc. 25.77% 17.59% 29.88% 12.12% 10.75%
Regeneron Pharmaceuticals Inc. 19.08% 27.91% 19.51% 20.13% 17.40%
Vertex Pharmaceuticals Inc. 19.34% 47.28% 12.99% -9.69% -59.19%
Zoetis Inc. 55.39% 65.35% 48.81% 55.21% 31.74%
ROE, Sector
Pharmaceuticals & Biotechnology 30.26% 28.24% 14.79% 23.42% 23.43%
ROE, Industry
Health Care 23.89% 21.64% 13.76% 19.15% 18.87%

Based on: 10-K (filing date: 2020-02-11), 10-K (filing date: 2019-02-12), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-14), 10-K (filing date: 2016-03-02).

1 2019 Calculation
ROE = 100 × Net income attributable to Illumina stockholders ÷ Total Illumina stockholders’ equity
= 100 × 1,002 ÷ 4,613 = 21.72%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Illumina Inc.’s ROE deteriorated from 2017 to 2018 and from 2018 to 2019.

Return on Assets (ROA)

Illumina Inc., ROA calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 29, 2019 Dec 30, 2018 Dec 31, 2017 Jan 1, 2017 Jan 3, 2016
Selected Financial Data (US$ in millions)
Net income attributable to Illumina stockholders 1,002  826  726  463  462 
Total assets 7,316  6,959  5,257  4,281  3,688 
Profitability Ratio
ROA1 13.70% 11.87% 13.81% 10.81% 12.52%
Benchmarks
ROA, Competitors2
Abbott Laboratories 5.43% 3.53% 0.63% 2.66% 10.72%
AbbVie Inc. 8.84% 9.58% 7.50% 9.01% 9.70%
Amgen Inc. 13.13% 12.64% 2.48% 9.95% 9.69%
Biogen Inc. 21.62% 17.52% 10.73% 16.19% 18.19%
Bristol-Myers Squibb Co. 2.65% 14.06% 3.00% 13.22% 4.93%
Eli Lilly & Co. 21.17% 7.36% -0.45% 7.05% 6.77%
Gilead Sciences Inc. 8.74% 8.57% 6.58% 23.70% 34.93%
Johnson & Johnson 9.59% 10.00% 0.83% 11.71% 11.55%
Merck & Co. Inc. 11.66% 7.53% 2.72% 4.11% 4.36%
Pfizer Inc. 9.72% 7.00% 12.40% 4.20% 4.16%
Regeneron Pharmaceuticals Inc. 14.29% 20.83% 13.67% 12.84% 11.34%
Vertex Pharmaceuticals Inc. 14.15% 33.57% 7.43% -3.87% -22.26%
Zoetis Inc. 12.99% 13.25% 10.06% 10.73% 4.28%
ROA, Sector
Pharmaceuticals & Biotechnology 9.66% 9.34% 5.20% 8.89% 9.61%
ROA, Industry
Health Care 8.69% 8.13% 5.22% 7.59% 7.84%

Based on: 10-K (filing date: 2020-02-11), 10-K (filing date: 2019-02-12), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-14), 10-K (filing date: 2016-03-02).

1 2019 Calculation
ROA = 100 × Net income attributable to Illumina stockholders ÷ Total assets
= 100 × 1,002 ÷ 7,316 = 13.70%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROA A profitability ratio calculated as net income divided by total assets. Illumina Inc.’s ROA deteriorated from 2017 to 2018 but then improved from 2018 to 2019 not reaching 2017 level.